FDA clears CAP-003 Parkinson’s gene therapy to be tested in trials
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has cleared a Parkinson's gene therapy, known as CAP-003, for testing in trials. This clearance allows the therapy to move forward in the development process. The therapy will now be tested to assess its safety and efficacy in treating Parkinson's disease.